Type 2 Endotypes in Airway Diseases
About one-third of COPD patients have inflammation patterns that respond to newer biologic drugs now available, opening treatment options previously unavailable.
This comprehensive review of T2 inflammatory endotypes in asthma and COPD summarizes the molecular landscape, approved biologic therapies (6 for asthma, 2 for T2-COPD), and emerging precision medicine strategies including next-generation allergen immunotherapy and trained immunity vaccines. The identification of T2-COPD as a distinct endotype in ~20-30% of COPD patients has direct implications for biologic therapy targeting in a historically undertreated disease subgroup.
What the study was
- Study design
- Narrative review; T2-high asthma and T2-COPD endotypes; biologic therapies; precision medicine approaches
- Population
- Patients with T2-high asthma and T2-COPD endotype (review scope)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Archivos de Bronconeumología
Why it surfaced
Good review of T2 endotype therapeutics in airway disease with clinical biologic treatment summary. Score 5 reflects narrative review design, publication date pre-dating current window (CRDT 2026-06-06 but publication 2026-05-23), and incremental rather than novel content.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.